BioNTech SE - HealthQuill

Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in an all-stock deal to expand the former’s mRNA-based cancer immunotherapy candidates.

BioNTech SE to acquire CureVac for $1.25 billion in all-stock deal

HQ Team June 12, 2025: Germany’s BioNTech SE will acquire CureVac N.V., which develops therapies based on messenger RNA, for $1.25 billion in.

by HealthQuill
June 12, 2025
0 Comments

US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation of an immunotherapy candidate to treat multiple tumour types.

Drugs Health Pharma

Bristol, BioNTech in $11.1b pact for immunotherapy candidate

HQ Team June 2, 2025: US-based Bristol Myers Squibb announced a $11.1 billion pact with Germany’s BioNTech SE for global co-development and co-commercialisation.

by HealthQuill
June 2, 2025
0 Comments

The US Food and Drug Administration has cleared Novavax’s updated Covid-19 vaccine for emergency use in adolescents 12 years of age or above, the regulator announced.

Drugs Health Pharma

Novavax gets FDA nod for updated Covid-19 vaccine for 12 years and above

HQ Team October 4, 2023: The US Food and Drug Administration has cleared Novavax’s updated Covid-19 vaccine for emergency use in adolescents 12.

by HealthQuill
October 4, 2023
0 Comments

German biotechnology company, BioNTech SE announced a $ 90 million program in partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine for mpox.

Drugs Health Pharma

Germany’s BioNTech, CEPI in $90m pact for mpox vaccine

HQ Team September 18, 2023: German biotechnology company, BioNTech SE announced a $ 90 million program in partnership with the Coalition for Epidemic.